IBE

15.695

+1.13%↑

ENGI

18.865

+1.23%↑

ELE

25.84

+1.25%↑

VER1

63.9

-0.47%↓

RED.ES

16.34

+0.55%↑

IBE

15.695

+1.13%↑

ENGI

18.865

+1.23%↑

ELE

25.84

+1.25%↑

VER1

63.9

-0.47%↓

RED.ES

16.34

+0.55%↑

IBE

15.695

+1.13%↑

ENGI

18.865

+1.23%↑

ELE

25.84

+1.25%↑

VER1

63.9

-0.47%↓

RED.ES

16.34

+0.55%↑

IBE

15.695

+1.13%↑

ENGI

18.865

+1.23%↑

ELE

25.84

+1.25%↑

VER1

63.9

-0.47%↓

RED.ES

16.34

+0.55%↑

IBE

15.695

+1.13%↑

ENGI

18.865

+1.23%↑

ELE

25.84

+1.25%↑

VER1

63.9

-0.47%↓

RED.ES

16.34

+0.55%↑

Search

STRATEC Biomedical AG

Open

26.35 -0.94

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.75

Max

26.7

Belangrijke statistieken

By Trading Economics

Inkomsten

11M

12M

Verkoop

24M

81M

K/W

Sectorgemiddelde

20.341

23.226

EPS

0.95

Dividendrendement

2.24

Winstmarge

14.203

Werknemers

1,386

EBITDA

16M

23M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+27.58% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.24%

3.65%

Volgende Winsten

19 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

12M

326M

Vorige openingsprijs

27.29

Vorige sluitingsprijs

26.35

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

STRATEC Biomedical AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jul 2025, 17:24 UTC

Marktinformatie

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

Peer Vergelijking

Prijswijziging

STRATEC Biomedical AG Prognose

Koersdoel

By TipRanks

27.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 34 EUR  27.58%

Hoogste 41 EUR

Laagste 28 EUR

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor STRATEC Biomedical AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Technische score

By Trading Central

N/A / 24.5Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over STRATEC Biomedical AG

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.